| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses
|
Kline, Kathryn A. F.
|
|
|
|
5 |
p. 384-393
|
article
|
| 2 |
Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions
|
DiNardo, Courtney
|
|
2019
|
|
5 |
p. 386-394
|
article
|
| 3 |
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia
|
Krecak, Ivan
|
|
|
|
5 |
p. 155-169
|
article
|
| 4 |
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
|
Duminuco, Andrea
|
|
|
|
5 |
p. 176-189
|
article
|
| 5 |
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms
|
Sullivan, Mia J.
|
|
|
|
5 |
p. 105-112
|
article
|
| 6 |
Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia
|
Aleem, Ahmed
|
|
|
|
5 |
p. 394-404
|
article
|
| 7 |
Approach to MPN Symptom Assessment
|
Geyer, Holly
|
|
2017
|
|
5 |
p. 381-388
|
article
|
| 8 |
Avapritinib in the Treatment of Systemic Mastocytosis: an Update
|
Below, Samantha
|
|
|
|
5 |
p. 464-472
|
article
|
| 9 |
BTK Inhibitors in Chronic Lymphocytic Leukemia
|
Gaballa, Sameh
|
|
|
|
5 |
p. 422-432
|
article
|
| 10 |
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
|
Pehlivan, Katherine C.
|
|
2018
|
|
5 |
p. 396-406
|
article
|
| 11 |
Challenges in Chronic Myeloid Leukemia Management in South America
|
Pagnano, Katia B.
|
|
|
|
5 |
p. 440-447
|
article
|
| 12 |
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
|
Ruella, Marco
|
|
2016
|
|
5 |
p. 368-384
|
article
|
| 13 |
Chromatin-Remodeled State in Lymphoma
|
Liu, Yuxuan
|
|
2019
|
|
5 |
p. 439-450
|
article
|
| 14 |
Chronic Myeloid Leukemia—the Promise of Tyrosine Kinase Inhibitor Discontinuation
|
Narra, Ravi Kishore
|
|
2017
|
|
5 |
p. 415-423
|
article
|
| 15 |
Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications
|
Yap, Kristofor
|
|
2019
|
|
5 |
p. 353-357
|
article
|
| 16 |
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
|
Baird, John H.
|
|
2018
|
|
5 |
p. 407-416
|
article
|
| 17 |
Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
|
Drusbosky, Leylah M.
|
|
2017
|
|
5 |
p. 478-483
|
article
|
| 18 |
Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms
|
Foucar, Charles Elliott
|
|
2017
|
|
5 |
p. 406-414
|
article
|
| 19 |
Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse
|
Ahmed, Aadil
|
|
|
|
5 |
p. 418-421
|
article
|
| 20 |
Emerging EZH2 Inhibitors and Their Application in Lymphoma
|
Lue, Jennifer K.
|
|
2018
|
|
5 |
p. 369-382
|
article
|
| 21 |
Familial MPN Predisposition
|
Tashi, Tsewang
|
|
2017
|
|
5 |
p. 442-447
|
article
|
| 22 |
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions
|
Sears-Smith, Megan
|
|
|
|
5 |
p. 158-166
|
article
|
| 23 |
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms
|
Badar, Talha
|
|
|
|
5 |
p. 113-120
|
article
|
| 24 |
How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera
|
Reiter, Andreas
|
|
2016
|
|
5 |
p. 356-367
|
article
|
| 25 |
IMiDs New and Old
|
Yamshon, Samuel
|
|
2019
|
|
5 |
p. 414-425
|
article
|
| 26 |
Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies
|
Falchi, Lorenzo
|
|
2017
|
|
5 |
p. 484-494
|
article
|
| 27 |
Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection
|
Sukswai, Narittee
|
|
2019
|
|
5 |
p. 368-375
|
article
|
| 28 |
Investigation and Management of Erythrocytosis
|
McMullin, Mary Frances
|
|
2016
|
|
5 |
p. 342-347
|
article
|
| 29 |
Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer
|
Achi, Hanadi El
|
|
2019
|
|
5 |
p. 358-367
|
article
|
| 30 |
Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia
|
Nazha, Aziz
|
|
2018
|
|
5 |
p. 341-347
|
article
|
| 31 |
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia
|
Hammond, Danielle
|
|
|
|
5 |
p. 405-417
|
article
|
| 32 |
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera
|
How, Joan
|
|
|
|
5 |
p. 473-482
|
article
|
| 33 |
Management of Chronic Myeloid Leukemia in Children and Young Adults
|
Ford, Maegan
|
|
|
|
5 |
p. 121-126
|
article
|
| 34 |
Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials
|
Stein, Brady L.
|
|
|
|
5 |
p. 483-489
|
article
|
| 35 |
Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies
|
Torka, Pallawi
|
|
2019
|
|
5 |
p. 426-438
|
article
|
| 36 |
Minimal Residual Disease Eradication in CML: Does It Really Matter?
|
Tantravahi, Srinivas K.
|
|
2017
|
|
5 |
p. 495-505
|
article
|
| 37 |
Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS
|
Nazha, Aziz
|
|
2017
|
|
5 |
p. 461-467
|
article
|
| 38 |
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
|
Yaghmaie, Marjan
|
|
2019
|
|
5 |
p. 395-404
|
article
|
| 39 |
Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender
|
Patterson-Fortin, Jeffrey
|
|
2017
|
|
5 |
p. 424-431
|
article
|
| 40 |
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
|
Beck, Kelsey
|
|
|
|
5 |
p. 201-215
|
article
|
| 41 |
Multi-Specific CAR Targeting to Prevent Antigen Escape
|
Walsh, Zachary
|
|
2019
|
|
5 |
p. 451-459
|
article
|
| 42 |
Navigating Ethical Practices in the Era of High Cost Hematology
|
Ertz-Archambault, Natalie
|
|
|
|
5 |
p. 401-407
|
article
|
| 43 |
Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020?
|
Sankar, Kamya
|
|
|
|
5 |
p. 391-400
|
article
|
| 44 |
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors
|
Waksal, Julian A.
|
|
|
|
5 |
p. 140-154
|
article
|
| 45 |
Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors
|
Economides, Minas P.
|
|
2019
|
|
5 |
p. 460-468
|
article
|
| 46 |
Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics
|
Shaver, Aaron C.
|
|
2017
|
|
5 |
p. 448-454
|
article
|
| 47 |
Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times
|
Patel, Sagar S.
|
|
2017
|
|
5 |
p. 455-460
|
article
|
| 48 |
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
|
Barbui, Tiziano
|
|
|
|
5 |
p. 455-463
|
article
|
| 49 |
Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing
|
Zuo, Zhuang
|
|
2019
|
|
5 |
p. 376-385
|
article
|
| 50 |
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature
|
Zhou, Amy
|
|
2017
|
|
5 |
p. 397-405
|
article
|
| 51 |
Real-world Management of CML: Outcomes and Treatment Patterns
|
Held, Nicole
|
|
|
|
5 |
p. 167-175
|
article
|
| 52 |
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
|
Dao, Kim-Hien T.
|
|
2017
|
|
5 |
p. 432-441
|
article
|
| 53 |
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
|
Odetola, Oluwatobi
|
|
|
|
5 |
p. 130-143
|
article
|
| 54 |
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma
|
Teo, Winnie Z. Y.
|
|
|
|
5 |
p. 190-200
|
article
|
| 55 |
Richter Transformation of Chronic Lymphocytic Leukemia—Are We Making Progress?
|
Audil, Hadiyah Y.
|
|
|
|
5 |
p. 144-157
|
article
|
| 56 |
Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis
|
Martin, Karlyn
|
|
2017
|
|
5 |
p. 389-396
|
article
|
| 57 |
Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma
|
Rhodes, Joanna
|
|
2018
|
|
5 |
p. 356-368
|
article
|
| 58 |
Social Media for Hematopathologists: Medical Practice Reinvented—#Hemepath
|
El Hussein, S.
|
|
|
|
5 |
p. 383-390
|
article
|
| 59 |
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations
|
Yuan, Ji
|
|
|
|
5 |
p. 121-129
|
article
|
| 60 |
Strategies for Predicting Response to Checkpoint Inhibitors
|
Zappasodi, Roberta
|
|
2018
|
|
5 |
p. 383-395
|
article
|
| 61 |
Targeting BCMA in Multiple Myeloma
|
Tan, Carlyn Rose
|
|
|
|
5 |
p. 367-383
|
article
|
| 62 |
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)
|
Wolfe, Heather R.
|
|
|
|
5 |
p. 448-454
|
article
|
| 63 |
Therapy for Chronic Myelomonocytic Leukemia in a New Era
|
Moyo, Tamara K.
|
|
2017
|
|
5 |
p. 468-477
|
article
|
| 64 |
The Role of PI3K Inhibition in Lymphoid Malignancies
|
Keudell, Gottfried von
|
|
2019
|
|
5 |
p. 405-413
|
article
|
| 65 |
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
|
Birgegård, Gunnar
|
|
2016
|
|
5 |
p. 348-355
|
article
|
| 66 |
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
|
Mora, Barbara
|
|
|
|
5 |
p. 127-139
|
article
|
| 67 |
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update
|
Bhatnagar, Neha
|
|
2016
|
|
5 |
p. 333-341
|
article
|
| 68 |
Treatment-Free Remission: the New Goal in CML Therapy
|
Atallah, Ehab
|
|
|
|
5 |
p. 433-439
|
article
|
| 69 |
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances
|
Vrooman, Lynda M.
|
|
2016
|
|
5 |
p. 385-394
|
article
|
| 70 |
Updates on Circulating Tumor DNA Assessment in Lymphoma
|
Darrah, Justin M.
|
|
2018
|
|
5 |
p. 348-355
|
article
|
| 71 |
Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
|
Eradat, Herbert
|
|
2019
|
|
5 |
p. 469-476
|
article
|
| 72 |
What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
|
Fernandez, Hugo F.
|
|
2016
|
|
5 |
p. 327-332
|
article
|
Journal description